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Liver Transplantation Under Tacrolimus In Infants, Children, Adults, 
and Seniors: Long-Term Results, Survival, and Adverse Events 
in 1000 Consecutive Patients 
A. Jain, J. Reyes, R. Kashyap, S. Rohal, T. Cacclarelli, J. McMichael, J. Rakela, T.E. Starzl, 
and J.J. Fung 
THE BENEFITS of tacrolimus in solid organ transplan-tation are well recognized. I-I> The aim of the present 
study is to examine the outcome of primary liver transplan-
tation (LTx) under tacrolimus for various age groups over a 
long-term in 1000 consecutive patients from a single center. 
MATERIAL 
The first 1000 primary L Tx recipients under tacrolimus from 
August 1989 to December 1992 were followed until August 1997 
(mean follow-up 77, range 56 to 96, months). The characteristics of 
the patients and immunosuppressive protocol have been described 
before in this population.7 There were 75 infants (s2 years), 91 
children (>2 s18 years), 630 adults (> 18 s60 years), and 204 
seniors «60 years). Of the recipients, 84.1% were hospital bound 
at the time of LTx, and 141 donors were above age 50 years. 
RESULTS 
Patient and graft survival for various age groups is shown in 
Table 1. The difference in patients survival and graft 
survival for various age groups were highly significant, 
p = .0006 and .0000, respectively (log rank). The level of 
immunosuppression, liver function (mean total bilirubin, 
AST, ALT, alkaline phosphatase, GGTP), and the renal 
function at various time points is shown in Table 2. 
Adverse Events 
The overall prevalence of hypertension requiring antihyper-
tensive medication, insulin dependent diabetes mellitus, 
hyperkalemia (k+ > 5.0 mEq/L), and mean cholesterol 
values are shown in Table 2. Three infants and children 
(2%) and 23 adults and seniors (2.8%) underwent kidney 
transplant for end-stage renal disease. In addition, 12 adults 
and seniors are currently on hemodialysis. Posttransplant 
Iymphoproliferative disorder (PTLD) was observed in 19 
infants and children (11.4%) and 16 adults and seniors 
(1.9%). Seventy-nine percent of infants and children and 
69% of adults and seniors are currently alive following the 
diagnosis of PTLD. DeNovo non lymphoid malignancy was 
observed in 57 adults and seniors (6.8%) but not in infants 
or children. These consisted of 20 squamous or basal cell 
skin cancers, 2 melanoma of the skin, 8 lung cancers, 7 
oropharyngeal cancers, 5 gastrointestinal cancers, 5 genito-
urinary cancers, 3 breast cancers, 2 Kaposi's sarcoma, and 5 
other miscellaneous cancers. Fifty-eight percent of these 
patients are still alive. Graft loss and death related to 
chronic rejection accounted for 13 adults and seniors 
(1.6%). Most of them had associated risk factors such as 
life-threatening sepsis requiring withholding of immuno-
suppression, cytomegalo or hepatitis C or hepatitis B viral 
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Table 1. Patient and Graft Survival 
Post LTx Months 3 12 24 
Patient survival (%) Infant 85 83 80 
Children 92 91 91 
Adults 93 85 80 
Seniors 65 75 71 
Overall 91 84 79 
Graft survival (%) Infant 83 80 77 
Children 86 85 85 
Adult 85 80 74 
Senior 79 70 66 
Overall 84 77 73 
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Table 2. Adverse Effects 
Months Post Ltx. 
Renal Function 
Serum creatinine mg/dV 
BUN mgldL 
Liver Function 
Total bilirubin mgldL" 
AST u/L" 
Alkaline phosphatase u/L" 
ALT uiL" 
GGTP uiL" 
Immunosuppression 
Tacrolimus Dose mgld" 
Tacrolimus level nglmL" 
Prednisone = 0 mgld (%) 
Prednisone> 10 mgld (%) 
Toxicity 
Hypertension (%) 
Diabetes (%) 
Hyperkalemia (%) 
Cholesterol mgldL' 
" Mean value. 
3 
1.7 
31 
1.0 
68 
205 
65 
177 
11 
1.0 
53 
28 
29 
24 
39 
102 
• Whole blood trough level; others are plasma trough level. 
6 
1.7 
30 
1.1 
48 
194 
62 
156 
10.5 
0.9 
57 
9 
29 
13 
44 
159 
infection, noncompliance of the patients taking immuno-
suppression. 
DISCUSSION 
The initial benefit of tacrolimus reported in our early 
experience has been maintained in the long term. While 
patient and graft survival in adults and seniors continue to 
drop at a rate of 3 to 4% every year beyond 2 years, survival 
for infant and children remains stable. Graft loss due to 
acute or chronic rejection is rare under tacrolimus-based 
immunoprophylaxis. The common causes of graft loss in the 
long term include recurrence of the disease, cardiorespira-
tory failure, cerebrovascular accidents, noncompliance of 
the patients. and denovo cancers. Relatively stable liver and 
renal function has been observed in the long term. About 
70% of the patients remain without steroids beyond 1 year. 
Nephrotoxicity leading to end-stage renal failure is less than 
five percent. Incidence of PTLD and denovo cancers are 
comparable with conventional immunosuppression.8•9 
Lesser incidence of acute or chronic rejection; lesser inci-
12 24 36 48 60 
1.7 1.6 1.6 1.7 1.7 
29 27 27 26 25 
1.1 0.8 0.8 1.0 0.9 
50 46 42 42 120 
168 152 142 144 131 
57 61 44 45 42 
127 121 125 129 120 
8.5 6.9 5.9 6.0 4.8 
0.8 0.7 0.6 0.7 9.7# 
67 72 71 66 67 
13 4 2 9 5 
30 37 36 41 46 
16 15 16 17 18 
42 46 40 38 35 
165 172 176 179 178 
dence hypercholesterolemia; and freedom from steroid in 
70% of the patients, from hirtutism, and from gum hyper-
plasia remains a considerable benefit of tacrolimus-based 
immunosuppression.6 
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